Liver problems with Abbott Laboratories Inc.’s discontinued attention deficit drug Cylert and other generic versions are too dangerous for the U.S. market, the Food and Drug Administration said on Monday.

“The agency has concluded that the overall risk of liver toxicity from Cylert and generic pemoline products outweighs the benefits of this drug,” the FDA said in a warning posted on its Web site.

In March, Abbott said it would no longer make the drug due to declining sales, but consumer advocates had argued it was too dangerous to be sold.

 


Comments


View Comments / Leave a Comment

This post currently has 2 comments.
You can read the comments or leave your own thoughts.


    Last reviewed: By John M. Grohol, Psy.D. on 24 Oct 2005
    Published on PsychCentral.com. All rights reserved.

APA Reference
Grohol, J. (2005). Discontinued ADD drug too risky: FDA. Psych Central. Retrieved on December 21, 2014, from http://psychcentral.com/blog/archives/2005/10/24/discontinued-add-drug-too-risky-fda/

 

Recent Comments
  • Seducelove: Women and men communicate in entirely different ways, especially these days that women have become more...
  • Mike: This was such a good read that I took time out to leave a comment (on an unknown website with an unknown...
  • Amanda: 2 days ago I started having flu like symptoms col hot headache nausea sore body extreme lack of energy the...
  • anonymous: Are you kidding me? A victim of this would actually choose this life? And that’s what I’m...
  • 707: So basically, if you can’t afford it, you’re screwed.
Subscribe to Our Weekly Newsletter


Find a Therapist
Enter ZIP or postal code



Users Online: 15897
Join Us Now!